Mixed glioma

disease
On this page

Also known as glioma, mixedglioma, mixed, malignantmixed glial neoplasmmixed glial tumormixed glial tumourmixed glioma (morphologic abnormality)mixed gliomasmixed neuroglial neoplasmmixed neuroglial tumormixed neuroglial tumour

Summary

Mixed glioma (MONDO:0003268) is a cancer and 17 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, carmustine, and etoposide phosphate. A subtype of glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemixed glioma
Mondo IDMONDO:0003268
DOIDDOID:5076
NCITC3903
SNOMED CT443937008
UMLSC0259783
MedGen75477
GARD0023431
Is cancer (heuristic)yes

Also known as: glioma, mixed · glioma, mixed, malignant · mixed glial neoplasm · mixed glial tumor · mixed glial tumour · mixed glioma · mixed glioma (morphologic abnormality) · mixed gliomas · mixed neuroglial neoplasm · mixed neuroglial tumor · mixed neuroglial tumour

Disease family

This is a subtype of glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmnervous system neoplasmneuroepithelial neoplasmgliomamixed glioma

Related subtypes (8): nerve sheath neoplasm, ependymal tumor, optic pathway glioma, astroblastoma, astrocytic tumor, low grade glioma, malignant glioma, diffuse glioma, H3 G34 mutant

Subtypes (3): mixed astrocytoma-ependymoma-oligodendroglioma, mixed astrocytoma-ependymoma, oligoastrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE18
PHASE24
Not specified3
PHASE1/PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00003473PHASE2COMPLETEDAntineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
NCT00004688PHASE2COMPLETEDPhase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
NCT00303849PHASE1/PHASE2COMPLETEDCarboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
NCT01095094PHASE2TERMINATEDRitonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
NCT02372409PHASE2TERMINATEDUsing MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
NCT00019578PHASE1COMPLETEDStereotactic Radiosurgery in Treating Patients With Brain Tumors
NCT00390299PHASE1COMPLETEDViral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00704080PHASE1COMPLETEDA Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
NCT01082926PHASE1COMPLETEDPhase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
NCT01250470PHASE1COMPLETEDVaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
NCT02101905PHASE1COMPLETEDLapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
NCT02238496PHASE1COMPLETEDPerifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
NCT04541225PHASE1TERMINATEDStudy of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT02976441EARLY_PHASE1WITHDRAWNAutologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
NCT04461938Not specifiedACTIVE_NOT_RECRUITINGCharacterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)
NCT05100173Not specifiedCOMPLETEDClinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
NCT05984667Not specifiedCOMPLETEDC-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
MERCAPTOPURINE ANHYDROUS43
CARMUSTINE41
ETOPOSIDE PHOSPHATE41
MANNITOL41
SODIUM THIOSULFATE41
SORBITOL41
STREPTOZOCIN41
ANTINEOPLASTON A1031
PERIFOSINE31
VOXTALISIB21
CHEMBL478312801
CHEMBL375320201
CHEMBL334937001